Roche Holding AG (RHHBY) Monday said Phase 3 STARGLO study of Columvi met its primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Patients who were treated with Columvi in combination with gemcitabine and oxaliplatin chemotherapy (GemOx) lived longer than those who were treated with MabThera/Rituxan in combination with GemOx.
Columvi has already received accelerated approval by the U.S. Food and Drug Administration and conditional marketing authorization from the European Commission to treat people with R/R DLBCL after two or more lines of systemic therapy.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.